File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios

TitleBayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios
Authors
KeywordsBayesian adaptive design
Bivariate binary model
Equivalence contour
Gibbs sampling
Trade-offs
Issue Date2006
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BIOM
Citation
Biometrics, 2006, v. 62 n. 3, p. 777-787+955 How to Cite?
AbstractA Bayesian adaptive design is proposed for dose-finding in phase I/II clinical trials to incorporate the bivariate outcomes, toxicity and efficacy, of a new treatment. Without specifying any parametric functional form for the drug dose-response curve, we jointly model the bivariate binary data to account for the correlation between toxicity and efficacy. After observing all the responses of each cohort of patients, the dosage for the next cohort is escalated, deescalated, or unchanged according to the proposed odds ratio criteria constructed from the posterior toxicity and efficacy probabilities. A novel class of prior distributions is proposed through logit transformations which implicitly imposes a monotonic constraint on dose toxicity probabilities and correlates the probabilities of the bivariate outcomes. We conduct simulation studies to evaluate the operating characteristics of the proposed method. Under various scenarios, the new Bayesian design based on the toxicity-efficacy odds ratio trade-offs exhibits good properties and treats most patients at the desirable dose levels. The method is illustrated with a real trial design for a breast medical oncology study. © 2006, The International Biometric Society.
Persistent Identifierhttp://hdl.handle.net/10722/146577
ISSN
2015 Impact Factor: 1.36
2015 SCImago Journal Rankings: 1.906
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYin, Gen_HK
dc.contributor.authorLi, Yen_HK
dc.contributor.authorJi, Yen_HK
dc.date.accessioned2012-05-02T08:37:08Z-
dc.date.available2012-05-02T08:37:08Z-
dc.date.issued2006en_HK
dc.identifier.citationBiometrics, 2006, v. 62 n. 3, p. 777-787+955en_HK
dc.identifier.issn0006-341Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/146577-
dc.description.abstractA Bayesian adaptive design is proposed for dose-finding in phase I/II clinical trials to incorporate the bivariate outcomes, toxicity and efficacy, of a new treatment. Without specifying any parametric functional form for the drug dose-response curve, we jointly model the bivariate binary data to account for the correlation between toxicity and efficacy. After observing all the responses of each cohort of patients, the dosage for the next cohort is escalated, deescalated, or unchanged according to the proposed odds ratio criteria constructed from the posterior toxicity and efficacy probabilities. A novel class of prior distributions is proposed through logit transformations which implicitly imposes a monotonic constraint on dose toxicity probabilities and correlates the probabilities of the bivariate outcomes. We conduct simulation studies to evaluate the operating characteristics of the proposed method. Under various scenarios, the new Bayesian design based on the toxicity-efficacy odds ratio trade-offs exhibits good properties and treats most patients at the desirable dose levels. The method is illustrated with a real trial design for a breast medical oncology study. © 2006, The International Biometric Society.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BIOMen_HK
dc.relation.ispartofBiometricsen_HK
dc.subjectBayesian adaptive designen_HK
dc.subjectBivariate binary modelen_HK
dc.subjectEquivalence contouren_HK
dc.subjectGibbs samplingen_HK
dc.subjectTrade-offsen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Administration & Dosageen_US
dc.subject.meshBayes Theoremen_US
dc.subject.meshBiometryen_US
dc.subject.meshBreast Neoplasms - Drug Therapy - Secondaryen_US
dc.subject.meshClinical Trials, Phase I As Topic - Statistics & Numerical Dataen_US
dc.subject.meshClinical Trials, Phase Ii As Topic - Statistics & Numerical Dataen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLikelihood Functionsen_US
dc.subject.meshLogistic Modelsen_US
dc.subject.meshModels, Statisticalen_US
dc.subject.meshOdds Ratioen_US
dc.subject.meshToxicology - Statistics & Numerical Dataen_US
dc.titleBayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratiosen_HK
dc.typeArticleen_HK
dc.identifier.emailYin, G: gyin@hku.hken_HK
dc.identifier.authorityYin, G=rp00831en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1541-0420.2006.00534.xen_HK
dc.identifier.pmid16984320-
dc.identifier.scopuseid_2-s2.0-33748795036en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33748795036&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume62en_HK
dc.identifier.issue3en_HK
dc.identifier.spage777en_HK
dc.identifier.epage787+955en_HK
dc.identifier.isiWOS:000240708300020-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYin, G=8725807500en_HK
dc.identifier.scopusauthoridLi, Y=15765879600en_HK
dc.identifier.scopusauthoridJi, Y=36570526400en_HK
dc.identifier.citeulike847467-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats